Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
203 participants
INTERVENTIONAL
2022-08-12
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\[68Ga\]N188, a novel molecular probe of PET imaging agent that targets Nectin-4, can be used in the diagnosis and research of a wide variety of Nectin-4 high-expression malignancies, including bladder cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
NCT06994078
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
NCT06648317
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
NCT05321316
68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma
NCT05902377
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
[68Ga]N188
Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-N188 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
[68Ga]N188
68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[68Ga]N188
68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18F-FDG PET/CT within 1 week;
* Signed written informed consent.
Exclusion Criteria
* Female patients plan to become pregnant within 6 months.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianhua ZHANG
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianhua Zhang, Dr.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
[68Ga]N188
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.